- Active, not recruiting
NCT03215524: Phase 2 - Daratumumab, Low-Dose Dex and Cyclophosphamide +/- Pomalidomide (DCDP)
Updated: May 6, 2022
A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide (DCDP)
This is a randomized phase II open label study of daratumumab, weekly low-dose oral cyclophosphamide and dexamethasone with or without pomalidomide in patients with relapsed and refractory multiple myeloma. The study consists of two arms. Patients will be randomized into ARM A and ARM B in a 1:1 ratio.
Sponsor: Canadian Myeloma Research Group
ClinicalTrials.gov Identifier: NCT03215524
Official Title: A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/study/NCT03215524
Daratumumab : National Cancer Institute
Daratumumab : MedlinePlus Drug Information
Daratumumab and Hyaluronidase-fihj Injection: National Cancer Institute
Daratumumab and Hyaluronidase-fihj Injection: MedlinePlus Drug Information
Dexamethasone : National Cancer Institute
Dexamethasone : MedlinePlus Drug Information
Pomalidomide: National Cancer Institute
Pomalidomide : MedlinePlus Drug Information
Biological: DCdP
Biological: DCd+P